



Contents lists available at ScienceDirect

Taiwanese Journal of Obstetrics & Gynecology

journal homepage: www.tjog-online.com

Short Communication

Oxidative stress and menopause-related hot flashes may be independent events



Gloria Bonaccorsi ^{a,b,1}, Arianna Romani ^{c,1}, Eleonora Cremonini ^c, Carlo M. Bergamini ^c,
 Maria Cristina Castaldini ^a, Enrica Fila ^{a,b}, Stefania Hanau ^c, Leo Massari ^{a,d},
 Carlo Cervellati ^{a,c,*}

^a Department of Morphology, Surgery and Experimental Medicine, Menopause and Osteoporosis Centre, University of Ferrara, Ferrara, Italy

^b Department of Morphology, Surgery and Experimental Medicine, Section of Gynaecology and Obstetrics, University of Ferrara, Ferrara, Italy

^c Department of Biomedical and Specialist Surgical Sciences, Section of Medical Biochemistry, Molecular Biology and Genetics, University of Ferrara, Ferrara, Italy

^d Department of Morphology, Surgery and Experimental Medicine, Section of Orthopaedic Clinic, University of Ferrara, Ferrara, Italy

ARTICLE INFO

Article history:

Accepted 4 September 2014

Keywords:

hot flashes
 menopause
 oxidative stress
 vasomotor symptoms

ABSTRACT

Objective: At present, there is growing demand for alternative, or additional, treatments to hormone replacement therapy for menopause-related hot flashes (HF). Antioxidant supplements have been recently proposed as possible candidates for this purpose, regardless of the absence of clear evidence in support of a link between these vasomotor symptoms and oxidative stress (OxS). The aim of our study was to evaluate the association between HF and OxS serum markers in a large sample of middle-aged women.

Materials and methods: We conducted a cross-sectional study on 245 perimenopausal and early postmenopausal women (age 45–60 years). The variables examined were presence of self-reported HF and levels of 8-iso-prostaglandin F_{2α}, 8-OH-deoxy-2'-guanosine, advanced oxidation protein products, total antioxidant power, uric acid, thiols, and paroxonase-1.

Results: Seventy-six women (31%) reported to suffer from HF (either medium or high intensity). None of the peripheral markers of OxS examined was found to be significantly associated with the presence of HF.
Conclusion: Taken together, our data suggest that systemic OxS might not be implicated with the onset of the climacteric vasomotor symptoms that most commonly affect women experiencing perimenopause and early postmenopause.

Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.

Introduction

At present, the etiology of menopausal vasomotor symptoms (VS) is not fully understood. However, emerging evidence suggests that these disturbances may occur within a reduced thermoneutral zone caused by an ineffective interaction between norepinephrine and 17 β-estradiol (E₂)-regulated α₂-adrenergic receptors [1,2]. Several studies have also indicated that the occurrence of VS may

represent not merely an effect of estrogen deficiency that can impair the quality of life, but also an early indicator of cardiovascular disease (CVD) risk [3,4]. Indeed, the presence and severity of night sweats, and, in particular, hot flashes (HF) is correlated with a proatherogenic condition featuring high blood pressure and cholesterol levels, as well as impaired endothelial function [3,4]. These findings have been interpreted by some authors as a clue of an implication of oxidative stress (OxS) in the etiology of these climacteric disturbances [5–7]. Indeed, it is now widely recognized that OxS plays a key role in all the stages of atherogenesis, from endothelial dysfunction to atheromatous plaque formation and rupture [8]. Furthermore, OxS is known as one of the most important contributors to the increased risk of CVD associated with menopausal transition [9]. Indeed, postmenopausal women are regarded as more vulnerable to OxS-related damage than women

* Corresponding author. Department of Biomedical and Specialist Surgical Sciences, Section of Medical Biochemistry, Molecular Biology and Genetics, University of Ferrara, via Borsari 46, 44121 Ferrara, Italy. Tel.: +39 0532 455444, +39 3480399087 (mobile); Fax: +39 0532 202723.

E-mail address: crvcr1@unife.it (C. Cervellati).

¹ These authors contributed equally to this work.

in reproductive age, not only because of their advanced age (aging is mutually associated with an increase in OxS) but also because of lower levels of E2, which is believed to act as an antioxidant [10–12].

On these bases, the aim of the present study was to investigate the association between HF and serum markers of both OxS-induced oxidative damage and antioxidant levels, in a sample of 245 healthy, nonobese women of perimenopausal and postmenopausal status.

Materials and methods

The present study included a subset of women enrolled in an observational research study by the Menopause and Osteoporosis Centre of the University of Ferrara (Ferrara, Italy), aimed at evaluating the physical and physiological correlates of OxS in women. These studies were undertaken within the framework of a protocol approved by the Medical School Ethics Committee, and in accordance with the Declaration of Helsinki (World Medical Association, <http://www.wma.net>), and the guidelines for Good Clinical Practice (European Medicines Agency, <http://www.ema.europa.eu>). Women were recruited upon signing an informed consent. Eligible participants were Caucasian women aged 45–60 years in perimenopause and early postmenopause (stage 1b or 2, assessed according to the Stages of Reproductive Aging Workshop bleeding criteria [13]). In particular, women in perimenopause experienced an increased and persistent variability of menstrual cycle length. Women reporting periods of amenorrhea longer than 11 months were classified as postmenopausal. Additionally, to confirm the assignment of menopausal status, we determined the blood levels of follicle-stimulating hormone and E2 for each woman, by using commercially available chemiluminescent microparticle immunoassays (Architect, Abbott Park, IL, USA), as previously described [14]. Exclusion criteria were factors known to influence OxS such as, the use of exogenous sexual hormones (including vaginal estrogens), dietary supplementation with nutritional antioxidants, vegetarian or vegan diet, and the diagnosis of a chronic disease (e.g., diabetes and hypertension).

Vasomotor symptoms

The presence of HF was assessed via a questionnaire at each visit and on the same day as the blood draw. At the beginning of the study, two questions were asked: (1) did the woman experience any HF in the 2 weeks prior to her visit? (2) If so, did she experience HF that can be classified as moderate to severe (i.e., having HF for more than 5 days/wk, with an average of more than 4 HF/d, and with at least six or more HF in 1 day)? [4]. Based on the responses to these questions, a dichotomous variable was created as follows:

- Absence of HF:
 - if the answer was “No” to question (1)
 - if the answer was “Yes” to question (1) but “No” to question (2)
- Presence of HF:
 - if the answer was “Yes” to both questions (1) and (2)

Women who were enrolled within the past two years of the study ($n = 85$) were additionally evaluated for VS using the Greene climacteric scale [15]. This scale is composed of 21 items that estimate VS, anxiety, depression, somatic symptoms, and sexuality. Each item is rated according to its severity on a 4-point scale: not at all (0), a little (1), quite a bit (2), and extremely (3). In this study, we only evaluated the two items (frequency of HF and sweating at night) that are used to calculate the subscore for VS (range 0–6).

Biochemical assays

Blood and urine were collected after overnight fast. Serum samples were obtained from blood by centrifugation (4650g for 20 minutes) and stored at -80°C until analysis.

The concentration of free 8-iso-prostaglandin F_{2α}, (8-isoPGF_{2α}) was assessed in urine by enzyme immunoassay (Cayman Chemical, Ann Arbor, MI, USA) following the manufacturer's protocol. Butylated hydroxytoluene was added to each aliquot (final concentration 0.005%) to prevent oxidation during processing.

Urine levels of 8-OH-deoxy-2'-guanosine (8-OH-dG) were measured by competitive immune-enzymatic assay (StressMarq Biosciences Inc., Victoria, BC, Canada). The concentrations of 8-isoPGF_{2α} and 8-OH-dG concentration were normalized to urinary creatinine concentration, and expressed as ng/mg creatinine.

The serum concentration (expressed as μM) of advanced oxidation protein products (AOPP) was determined by spectrophotometric detection according to Capeillère-Blandin et al [16].

The collective contribution of nonenzymatic antioxidants (vitamins A, E, and C, uric acid, etc.) was measured by serum total antioxidant power (TAP) by ferric reduction/antioxidant power (FRAP) method [17] and the results of this colorimetric assay were expressed as FRAP units, where 1 FRAP unit corresponds to the reduction of 100μM of Fe³⁺ reduced to Fe²⁺ in 6 minutes.

The concentration of serum uric acid (μM) was determined by direct colorimetric enzymatic method in which uric acid was oxidized by uricase coupled with peroxidase [18].

Total concentration of serum thiols (μM) was determined by colorimetric DTNB-based assay as described by Hu [19]. The measurement of serum paraoxonase-1 (PON-1) basal activity was performed by using paraoxon as substrate as described elsewhere [20]. PON-1 basal activity was expressed as U/mL, where one unit is equivalent to 1 nmol of paraoxon hydrolysed/min.

Statistical analysis

SPSS 17.00 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Unpaired Student *t* test (for normal variables) and Mann–Whitney *U* test (for non-normal variables) were used to identify significant differences in the two sample groups considered. The Chi-square test was used to compare differences in categorical variables. Spearman correlation analysis was implemented for checking if ordinal variables (Greene climacteric subscale for VS) were related to continuous variables (levels of OxS markers). A two-tailed $p < 0.05$ was considered statistically significant.

Results

The main characteristics, as well as the mean serum levels of OxS markers, of the enrolled women subdivided according to presence ($n = 76$, 31%) or absence ($n = 169$, 69%) of HF are reported in Table 1. Based on these results, it is clear that the two sample subgroups are very similar in age, years since menopause, physical features, and the levels of sex hormones. Likewise, Mann–Whitney *U* test showed that none of the OxS markers examined was significantly different between the two given subgroups.

In line with the aforementioned results, there was no significant correlation between OxS markers and VS score obtained by the Greene climacteric VS subscale, in the subset of 85 women who were enrolled in the last two years of the study (Table 2).

Discussion

The assessment of OxS in living organisms represents a crucial analytical challenge, mainly because the direct determination of

Table 1
General characteristics and oxidative stress markers of the study participants.

Characteristics	All women (n = 245)	Presence of hot flashes		p
		Absent (n = 169)	Present (n = 76)	
Age (y)	53.3 ± 4.2	53.4 ± 4.2	53.5 ± 4.3	0.879
Time since menopause (y)	2.4 (1.0–4.4)	2.4 (1.0–4.0)	2.2 (1.0–5.8)	0.285
Age at menarche (y)	12.0 (11.0–13.0)	12.0 (11.0–13.0)	12.0 (11.0–13.2)	0.258
E2 (pg/mL)	10.0 (6.0–28.5)	11.0 (6.0–28.0)	8.0 (6.0–39.0)	0.251
FSH (mIU/mL)	69.5 ± 30.6	66.4 ± 30.2	72.1 ± 25.7	0.090
BMI (kg/m ²)	24.9 ± 3.6	25.1 ± 3.8	24.9 ± 3.6	0.356
Waist circumference (cm)	85.1 ± 10.4	85.5 ± 9.8	84.1 ± 11.6	0.258
Hypertension (%)	11.3	13.0	7.4	0.221
Smokers (%)	13.9	12.3	17.6	0.284
Oxidative stress markers				
8-isoPGF2 α (ng/mg creatinine)	1.21 ± 0.10	1.19 ± 0.12	1.26 ± 1.10	0.752
8-OH-dG (ng/mg creatinine)	164.0 ± 100.9	159.0 ± 97.4	174.1 ± 109.4	0.651
AOPP (μ M)	221 (188–280)	224 (187–285)	217 (187–266)	0.416
TAP (FRAP unit)	709.6 ± 153.9	711.9 ± 157.0	704.7 ± 148.1	0.755
Uric acid (mM)	80 (46–105)	79 (59–105)	83 (63–111)	0.272
Thiols (μ M)	209 (162–233)	206 (161–234)	216 (179–231)	0.828
PON-1 (U/L)	106 (61–177)	105 (60–173)	117 (59–196)	0.923

Data are expressed as mean ± standard deviation/median (interquartile range) when the variable was normally/not normally distributed, respectively.

8-isoPGF2 α = 8-iso-prostaglandin F2 α ; 8-OH-dG = 8-OH-deoxy-2'-guanosine; AOPP = advanced oxidation protein products; BMI = body mass index; E2 = 17 β -estradiol; FSH = follicle stimulating hormone; PON-1 = paraoxonase 1; TAP = total antioxidant power.

reactive species, which cause this pathophysiological condition, is impracticable in large-scale population studies [21]. The only feasible approach is the indirect assessment of these species through the quantification of by-products of oxidative damage towards biomolecules such as lipids, DNA, and proteins [21,22]. Among the potential markers that have been identified so far, urinary 8-isoPGF2 α and 8-OH-dG, which are indicators of lipid and DNA oxidative challenge, respectively, have proven to be the most reliable [22]. However, thus far, there has been no widespread agreement on which marker should be measured for assessing OxS-induced protein damage. The recently described AOPP, have emerged as promising markers of this type of molecular injury, because of their strong association with CVD and several other OxS-related disorders [23].

We thoroughly considered the aforementioned methodological issues in the selection of markers to employ in the present study, which aimed to investigate the interplay between OxS and HF. In study this, we compared the levels of urinary 8-isoPGF2 α and 8-OH-dG, along with serum AOPP, between perimenopausal and early postmenopausal women with or without complaints of HF. Our analyses indicate that there is no significant difference in OxS pattern between these two groups (Table 1), and therefore, no association between HF and systemic OxS.

Our negative results are in apparent contradiction to those of other studies suggesting that menopause, as well as related

disturbances and diseases, might be linked to the accumulation of oxidative damage [5,24]. In reality, it is worth noting that the *in vivo* antioxidant effectiveness of endogen E2, which is the conceptual basis in support of this association [5,10–12], is still far from being definitely demonstrated, mainly because of the controversial epidemiological data on this topic. Indeed, while some large studies showed increased levels of urinary 8-OH-dG in postmenopausal women compared to women of reproductive age [24,25], other investigators did not observe any significant differences in the levels of the more sensitive urinary 8-isoPGF2 α [26,27] (lipids are more sensitive to a rise in OxS than DNA [22]) or AOPP [28]. Moreover, mixed results were obtained using different markers of lipoperoxidation, such as serum malondialdehyde or lipid hydroperoxides, which, depending on the study, showed higher [29], unvaried [14,30], or lower levels of oxidation [28], in postmenopausal compared to premenopausal women. The well-documented low specificity and sensitivity of these indexes (especially when they are not measured by using a fluorimetric-high-performance liquid chromatography approach [22]), the lack of consideration of potential confounders of statistical analysis (including, but not limited to, body fat parameters [30,31]) as well as the limited sample size, might explain the high level of inconsistency in these results.

Similar methodological and study design limitations, as well as differences in sample characteristics, might also account for the discrepancy between our results and those of the study by Leal et al [6] that examined the correlation between HF and OxS. In Leal et al's [6] work, the lipoperoxide levels (measured colorimetrically) positively correlated with the presence of HF in a small (n = 45) sample of postmenopausal women. Moreover, at variance with this investigation, in our study women with HF were not deficient in either dietary (collectively measured by total antioxidant power) or endogenous (thiols, uric acid, and PON-1) antioxidants, when compared to those without these symptoms. This finding is in line with observations from other studies exploring the effects of antioxidant supplementation [32–35] on the frequency and severity of HF. Notably, the amelioration of flushing intensity after treatment with α -tocopherol reported in one of these studies [32] has been attributed to the nonantioxidant actions of this vitamin, in particular, the ability to regulate the hypothalamic release of norepinephrine, which, in turn, plays a role in core body temperature control.

Table 2
Relationship between oxidative stress markers and Greene climacteric subscale for VS (Spearman correlation coefficients, r) in a subsample of 85 perimenopausal and early postmenopausal women.^a

	r	p
8-isoPGF2 α	−0.164	0.199
8-OH-dG	0.091	0.488
AOPP	0.015	0.902
TAP	−0.114	0.338
Uric acid	−0.027	0.821
Thiols	0.046	0.713
PON-1	−0.070	0.609

8-isoPGF2 α = 8-iso-prostaglandin F2 α ; 8-OH-dG = 8-OH-deoxy-2'-guanosine; AOPP = advanced oxidation protein products; PON-1 = paraoxonase 1; TAP = total antioxidant power.

^a Frequency of women according to Greene vasomotor symptoms score: Score = 0, n = 34; score = 1, n = 19; score = 2, n = 9; score = 3, n = 7; score = 4, n = 7; score = 5, n = 4; score = 6, n = 5.

The most important limitation regarding VS evaluation is that these symptoms cannot be measured objectively but only by self-reported data. At the start, our study was further affected by a less comprehensive estimation of VS mostly because of the lack of evaluation of the frequency of night sweats. In an attempt to overcome this drawback, VS of women enrolled during the last part of the study protocol of the study were evaluated by Greene VS subscale (1 of the 5 subscales of the Greene climacteric scale). In line with the data obtained with the dichotomous variable for HF, no significant correlations emerged between OxS markers and, thus, VS score (Table 2). Specific limitations of our study lied in its cross-sectional design, which prevents us from reaching a definitive appreciation of a link among factors considered in the analysis (a longitudinal approach is more valuable for this purpose), and the unequal size of the subgroups, which could affect the reliability of statistical outcomes. However, the latter limitation was, at least partially, overcome by the use of a nonparametric test such as the Mann–Whitney *U* test, which is regarded as the most appropriate tool for the analysis of difference between groups with this feature. Finally, it is worth pointing out that the absence of a universal biomarker for OxS detection remarkably affects the reliability of our results.

Conclusion

To the best of our knowledge, this study is among the first to investigate the potential interaction between HF and OxS in a, relatively, large sample of healthy perimenopausal and early postmenopausal women. Globally taken, our data did not support the existence of an association between these typical climacteric symptoms and the pathophysiological condition. However, we are aware that further investigations of longitudinal design are needed to confirm our results.

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

The study was supported by Local Research Project grant from University of Ferrara.

The authors thank Maria Grazia Bonora for her skilled organization of clinical protocol. They also want to thank Monica Squerzanti for her meaningful contribution in data collection and processing.

References

- [1] Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. *Am J Obstet Gynecol* 1999;181:66–70.
- [2] Brück K, Hinckel P. Thermoregulatory noradrenergic and serotonergic pathways to hypothalamic units. *J Physiol* 1980;304:193–202.
- [3] Bechlioulis A, Naka KK, Kalantaridou SN, Kaponis A, Papanikolaou O, Vezyraki P, et al. Increased vascular inflammation in early menopausal women is associated with hot flush severity. *J Clin Endocrinol Metab* 2012;97:E760–4.
- [4] Gast GCM, Grobbee DE, Pop VJ, Keyzer JJ, Wijnands-van Gent CJ, et al. Menopausal complaints are associated with cardiovascular risk factors. *Hypertension* 2008;51:1492–8.
- [5] Miquel J, Ramírez-Boscá A, Ramírez-Bosca JV, Alperi JD. Menopause: a review on the role of oxygen stress and favorable effects of dietary antioxidants. *Arch Gerontol Geriatr* 2006;42:289–306.
- [6] Leal M, Díaz J, Serrano E, Abellán J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flashes. *Obstet Gynecol* 2000;95:804–9.
- [7] Van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. *Eur Heart J* 2005;26:1358–61.
- [8] Lee R, Margaritis M, Channon KM, Antoniadis C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. *Curr Med Chem* 2012;19:2504–20.
- [9] Pansini F, Mollica G, Bergamini CM. Management of the menopausal disturbances and oxidative stress. *Curr Pharm Des* 2005;11:2063–73.
- [10] Sánchez-Rodríguez MA, Zacarías-Flores M, Arronte-Rosales A, Correa-Muñoz E, Mendoza-Núñez VM. Menopause as risk factor for oxidative stress. *Menopause* 2012;19:361–7.
- [11] Sack MN, Rader DJ, Cannon 3rd RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. *Lancet* 1994;343:269–70.
- [12] Cervellati C, Bonaccorsi G, Cremonini G, Bergamini CM, Patella A, Castaldini C, et al. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women. *Clin Chem Lab Med* 2013;51:333–8.
- [13] Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Menopause* 2001;8:402–7.
- [14] Cervellati C, Pansini FS, Bonaccorsi G, Bergamini CM, Patella A, Casali F, et al. 17 β -Estradiol levels and oxidative balance in a population of pre-, peri- and post-menopausal women. *Gynecol Endocrinol* 2011;27:1028–32.
- [15] Greene JG. Constructing a standard climacteric scale. *Maturitas* 2008;61:78–84.
- [16] Capeillère-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advanced oxidized protein products. *Biochim Biophys Acta* 2004;1689:91–102.
- [17] Cervellati C, Cremonini E, Bosi C, Magon S, Zurlo A, Bergamini CM, et al. Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimers Disease. *Curr Alzheimer Res* 2013;10:365–72.
- [18] Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4 aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. *Clin Chem* 1980;26:227–31.
- [19] Hu ML. Measurement of protein thiol groups and glutathione in plasma. *Methods Enzymol* 1994;233:380–5.
- [20] Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. *Clin Chim Acta* 2004;352:37–47.
- [21] Swartz HM, Khan N, Khramtsov VV. Use of electron paramagnetic resonance spectroscopy to evaluate the redox state *in vivo*. *Antioxid Redox Signal* 2007;9:1757–71.
- [22] Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? *Free Radic Biol Med* 2005;38:698–710.
- [23] Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2007;77:188–92.
- [24] Nakano M, Kawanishi Y, Kamohara S, Uchida Y, Shiota M, Inatomi Y, et al. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. *Free Radic Biol Med* 2003;42:289–306.
- [25] Sakano N, Wang DH, Takahashi N, Wang B, Sauriasari R, Kanbara S, et al. Oxidative stress biomarkers and lifestyles in Japanese healthy people. *J Clin Biochem Nutr* 2009;44:185–95.
- [26] Dorjgochoo T, Gao YT, Chow WH, Shu XO, Yang G, Cai Q, et al. Obesity, age, and oxidative stress in middle-aged and older women. *Antioxid Redox Signal* 2011;14:2453–60.
- [27] Sowers M, McConnell D, Jannausch ML, Randolph JF, Brook R, Gold EB, et al. Oestrogen metabolites in relation to isoprostanes as a measure of oxidative stress. *Clin Endocrinol (Oxford)* 2008;68:806–13.
- [28] Victorino VJ, Panis C, Campos FC, Cayres RC, Colado-Simão AN, Oliveira SR, et al. Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women. *Age (Dordr)* 2013;35:1411–21.
- [29] Signorelli SS, Neri S, Sciacchitano S, Pino LD, Costa MP, Marchese G, et al. Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. *Maturitas* 2003;53:77–82.
- [30] Pansini F, Cervellati C, Guariento A, Stacchini MA, Castaldini C, Bernardi A, et al. Oxidative stress, body fat composition and endocrine status in pre- and postmenopausal women. *Menopause* 2008;15:112–8.
- [31] Mittal PC, Kant R. Correlation of increased oxidative stress to body weight in disease-free postmenopausal women. *Clin Biochem* 2009;42:1007–11.
- [32] Ziaei S, Kazemnejad A, Zareai M. The effect of vitamin E on hot flashes in menopausal women. *Gynecol Obstet Invest* 2007;64:204–7.
- [33] Ye YB, Wang ZL, Zhuo SY, Lu W, Liao HF, Verbruggen M, et al. Soy germ isoflavones improve menopausal symptoms but have no effect on blood lipids in early postmenopausal Chinese women: a randomized placebo-controlled trial. *Menopause* 2012;19:791–8.
- [34] Verhoeven MO, van der Mooren MJ, van de Weijer PH, Verdegem PJ, van der Burg LM, Kenemans P, et al. Effect of a combination of isoflavones and *Actaea racemosa* Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. *Menopause* 2005;12:412–20.
- [35] Scoglio S, Benedetti S, Canino C, Santagni S, Rattighieri E, Chierchia E, et al. Effect of a 2-month treatment with Klamini[®], a Klamath algae extract, on the general well-being, antioxidant profile and oxidative status of postmenopausal women. *Gynecol Endocrinol* 2009;25:235–40.